A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin α<sub>v</sub>β<sub>3</sub>, ± dacarbazine in patients with stage IV metastatic melanoma

Hersey, Peter; A. Sosman, Jeffrey; O’Day, Steven; Richards, Jon; Y. Bedikian, Agop; González, René; H. Sharfman, William; Weber, Robert; F. Logan, Theodore; Buzoianu, Manuela; Hammershaimb, Luz; M. Kirkwood, John

doi:10.1002/cncr.24821

Public

A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin αvβ3, ± dacarbazine in patients with stage IV metastatic melanoma

Published in Cancer • Jan 27, 2010

Authors:

Peter Hersey

Jeffrey A. Sosman

Steven O’Day

Abstract

BACKGROUND: The alpha (v) beta (3) (alpha(v)beta(3)) integrin is involved in intracellular signaling regulating cell proliferation, migration, and differentiation and is important for tumor-induced angiogenesis. METHODS: This phase 2, randomized, open-label, 2-arm study was designed to capture safet...

Subject

Dacarbazine

Medicine

Melanoma

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!